These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38689134)

  • 1. Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.
    Ahn YJ; Maya J; Singhal V
    Curr Obes Rep; 2024 Jun; 13(2):295-312. PubMed ID: 38689134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard.
    San Giovanni CB; Sweeney B; Skelton JA; Kelsey MM; Kelly AS
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2103-2113. PubMed ID: 33901290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy in pediatric obesity: current evidence and landscape.
    Singhal V; Sella AC; Malhotra S
    Curr Opin Endocrinol Diabetes Obes; 2021 Feb; 28(1):55-63. PubMed ID: 33186194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
    Page LC; Freemark M
    Curr Obes Rep; 2020 Dec; 9(4):391-401. PubMed ID: 33085056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Weight Management in the Era of Adolescent Obesity.
    Raman V; Gupta A; Ashraf AP; Breidbart E; Gourgari E; Kamboj M; Kohn B; Krishnan S; Lahoti A; Matlock K; Mehta S; Mistry S; Miller R; Page L; Reynolds D; Han JC
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2716-2728. PubMed ID: 35932277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy in the Management of Pediatric Obesity.
    Kelly AS; Fox CK
    Curr Diab Rep; 2017 Aug; 17(8):55. PubMed ID: 28646356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of weight loss in children and adolescents with obesity.
    Calcaterra V; Rossi V; Mari A; Casini F; Bergamaschi F; Zuccotti GV; Fabiano V
    Pharmacol Res; 2022 Nov; 185():106471. PubMed ID: 36174963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US.
    Czepiel KS; Perez NP; Campoverde Reyes KJ; Sabharwal S; Stanford FC
    Front Endocrinol (Lausanne); 2020; 11():290. PubMed ID: 32477270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of pharmacologic treatment for pediatric obesity.
    Chao AM; Wadden TA; Berkowitz RI
    Expert Opin Drug Saf; 2018 Apr; 17(4):379-385. PubMed ID: 29411652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-Label Prescribing for Children with Migraines in U.S. Ambulatory Care Settings.
    Lai LL; Koh L; Ho JA; Ting A; Obi A
    J Manag Care Spec Pharm; 2017 Mar; 23(3):382-387. PubMed ID: 28230456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.
    Kelly AS; Fox CK; Rudser KD; Gross AC; Ryder JR
    Int J Obes (Lond); 2016 Jul; 40(7):1043-50. PubMed ID: 27113643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in prescribing anti-obesity pharmacotherapy for paediatric weight management: Data from the POWER Work Group.
    Borzutzky C; King E; Fox CK; Stratbucker W; Tucker J; Yee JK; Kumar S; Cuda S; Sweeney B; Kirk S; On Behalf Of The Power Work Group
    Pediatr Obes; 2021 Jan; 16(1):e12701. PubMed ID: 32877010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future pharmacotherapies for obesity in children and adolescents.
    Kelly AS
    Nat Rev Endocrinol; 2023 Sep; 19(9):534-541. PubMed ID: 37337008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment modalities for obesity.
    Grandone A; Di Sessa A; Umano GR; Toraldo R; Miraglia Del Giudice E
    Best Pract Res Clin Endocrinol Metab; 2018 Aug; 32(4):535-549. PubMed ID: 30086873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
    Jensterle M; Janež A
    Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term drug treatment for obesity: a systematic and clinical review.
    Yanovski SZ; Yanovski JA
    JAMA; 2014 Jan; 311(1):74-86. PubMed ID: 24231879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interventions for the treatment of obesity in children and adolescents.
    Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of medications approved for chronic weight management.
    Fujioka K
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the risks and the benefits of current and emerging weight-loss medications?
    Robinson JR; Niswender KD
    Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.